Valneva: promising pediatric vaccine against chikungunya
(CercleFinance.com) - Valneva yesterday announced positive results from its Phase 2 clinical study evaluating the safety and immunogenicity of two different doses of its single injection chikungunya vaccine, Ixchiq, in 304 children.
The results of this study could lead to the launch of a pivotal Phase 3 study in children, which the Company plans to initiate in the fourth quarter of 2025, with the aim of enabling future regulatory submissions for this age group.
Study VLA1553-221 met its primary endpoint, demonstrating that the vaccine was well tolerated by children aged between one and eleven years old, irrespective of the dose of vaccine received (full or half dose) or previous infection with the chikungunya virus.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The results of this study could lead to the launch of a pivotal Phase 3 study in children, which the Company plans to initiate in the fourth quarter of 2025, with the aim of enabling future regulatory submissions for this age group.
Study VLA1553-221 met its primary endpoint, demonstrating that the vaccine was well tolerated by children aged between one and eleven years old, irrespective of the dose of vaccine received (full or half dose) or previous infection with the chikungunya virus.
Copyright (c) 2025 CercleFinance.com. All rights reserved.